Temat: "Oxonic Acid" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Efficacy and Safety of Additional S-1 Chemotherapy to S-1 Plus Oxaliplatin Regimen Chemotherapy for Stage III Gastric Carcinoma after Radical Resection.
Autorzy:: Chen C; General Surgery Department, First People's Hospital of Huzhou, Huzhou, People's Republic of China.
Tang CW; General Surgery Department, First People's Hospital of Huzhou, Huzhou, People's Republic of China.
Huang SX; General Surgery Department, First People's Hospital of Huzhou, Huzhou, People's Republic of China.
Shen CL; Out-Patient Department, First People's Hospital of Huzhou, Huzhou, People's Republic of China.; Pokaż więcej
Źródło:: Cancer investigation [Cancer Invest] 2022 Jan; Vol. 40 (1), pp. 73-80. Date of Electronic Publication: 2021 Oct 21.
Typ publikacji:: Journal Article
MeSH Terms:: Antimetabolites, Antineoplastic/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Oxaliplatin/*therapeutic use
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*surgery
Tegafur/*therapeutic use
Antimetabolites, Antineoplastic/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Oxaliplatin/pharmacology ; Oxonic Acid/pharmacology ; Progression-Free Survival ; Retrospective Studies ; Stomach Neoplasms/mortality ; Tegafur/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
Autorzy:: Yen CC; Division of Hematology/ Oncology, Department of Internal Medicine, National Cheng Kung University Hospital Douliou Branch, Yunlin, Taiwan.; Institute of Clinical Medicine, School of Medicine, National Cheng Kung University, Tainan, Taiwan.
Shan YS; Institute of Clinical Medicine, School of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chao YJ; Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Liao TK; Department of Surgery, National Cheng Kung University Hospital Douliou Branch, YunLin, Taiwan.
Chen IS; Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Huang HY; Division of Colorectal Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Liu IT; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Sheng-Li Road, Tainan, 70403, Taiwan.
Yen CJ; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Sheng-Li Road, Tainan, 70403, Taiwan. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Jul 09; Vol. 21 (1), pp. 796. Date of Electronic Publication: 2021 Jul 09.
Typ publikacji:: Journal Article
MeSH Terms:: Chemotherapy, Adjuvant/*methods
Oxonic Acid/*therapeutic use
Pyridines/*therapeutic use
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*surgery
Tegafur/*therapeutic use
Aged ; Drug Combinations ; Humans ; Middle Aged ; Oxonic Acid/pharmacology ; Propensity Score ; Pyridines/pharmacology ; Retrospective Studies ; Tegafur/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer.
Autorzy:: Ye Z; Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Zeng Y; Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Wei S; Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Wang Y; Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Lin Z; Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Chen S; Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Wang Z; Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Chen S; Department of Fujian Provincial Key Laboratory of Tumor Biotherapy, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China.
Chen L; Department of Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, 350014, Fujian Province, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Jun 15; Vol. 21 (1), pp. 702. Date of Electronic Publication: 2021 Jun 15.
Typ publikacji:: Clinical Trial, Phase II; Journal Article
MeSH Terms:: Oxaliplatin/*therapeutic use
Oxonic Acid/*therapeutic use
Pyridines/*therapeutic use
Stomach Neoplasms/*drug therapy
Tegafur/*therapeutic use
Adult ; Aged ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Oxaliplatin/pharmacology ; Oxonic Acid/pharmacology ; Pyridines/pharmacology ; Stomach Neoplasms/mortality ; Survival Analysis ; Tegafur/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.
Autorzy:: Endo S; Department of Digestive Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan. .
Terazawa T; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, Japan.
Goto M; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, Japan.
Tanaka R; Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka, Japan.
Kato T; Department of Surgery, National Hospital Organization Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-ku, Osaka, Japan.
Fujitani K; Department of Gastroenterological Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-ku, Osaka, Japan.
Kawakami H; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka, Japan.
Sakai D; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.
Kurokawa Y; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.
Tsujinaka T; Department of Surgery, Izumi City General Hospital, 4-5-1 Wake-cho, Izumi, Osaka, Japan.
Shimokawa T; Clinical Study Support Center, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, Japan.
Satoh T; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, Japan.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2022 Jul 23; Vol. 22 (1), pp. 811. Date of Electronic Publication: 2022 Jul 23.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Neoadjuvant Therapy*/methods
Stomach Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant/methods ; Cisplatin ; Clinical Trials, Phase II as Topic ; Docetaxel ; Drug Combinations ; Gastrectomy/methods ; Humans ; Multicenter Studies as Topic ; Oxaliplatin/therapeutic use ; Oxonic Acid ; Prospective Studies ; Tegafur

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
Autorzy:: Zhang L; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhang J; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Wang Y; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Li W; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu S; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Li Q; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu Y; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Liu T; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Cui Y; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. .; Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China. .; Pokaż więcej
Źródło:: BMC gastroenterology [BMC Gastroenterol] 2022 Jun 14; Vol. 22 (1), pp. 296. Date of Electronic Publication: 2022 Jun 14.
Typ publikacji:: Journal Article
MeSH Terms:: Peritoneal Neoplasms*/drug therapy
Peritoneal Neoplasms*/etiology
Peritoneal Neoplasms*/surgery
Stomach Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Combinations ; Gastrectomy ; Humans ; Oxaliplatin/therapeutic use ; Oxonic Acid/therapeutic use ; Tegafur/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Autorzy:: Jiang Z; Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. No, 17, Panjiayuannanli Street, Chaoyang District, Beijing, 100021, China.
Zhou A; Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. No, 17, Panjiayuannanli Street, Chaoyang District, Beijing, 100021, China.
Sun Y; Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. No, 17, Panjiayuannanli Street, Chaoyang District, Beijing, 100021, China.
Zhang W; Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. No, 17, Panjiayuannanli Street, Chaoyang District, Beijing, 100021, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2022 Mar 09; Vol. 22 (1), pp. 253. Date of Electronic Publication: 2022 Mar 09.
Typ publikacji:: Clinical Trial, Phase II; Journal Article
MeSH Terms:: Esophagogastric Junction*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Oxaliplatin/*administration & dosage
Oxonic Acid/*administration & dosage
Stomach Neoplasms/*drug therapy
Tegafur/*administration & dosage
Aged ; China ; Drug Administration Schedule ; Drug Combinations ; Follow-Up Studies ; Humans ; Middle Aged ; Progression-Free Survival ; Stomach Neoplasms/mortality ; Survival Rate ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
Autorzy:: Shi M; Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Yang Z; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Lu S; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Liu W; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Ni Z; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Yao X; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Hua Z; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Feng R; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Zheng Y; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Wang Z; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Sah BK; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Chen M; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Zhu Z; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
He C; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Li C; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Zhang J; Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.; State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yan C; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China. .
Yan M; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China.
Zhu Z; Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin er Road, Shanghai, 200025, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Dec 18; Vol. 21 (1), pp. 1344. Date of Electronic Publication: 2021 Dec 18.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Peritoneal Neoplasms/*drug therapy
Stomach Neoplasms/*drug therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Drug Combinations ; Female ; Humans ; Infusions, Parenteral ; Male ; Middle Aged ; Neoplasm Staging ; Oxaliplatin/administration & dosage ; Oxaliplatin/adverse effects ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/secondary ; Peritoneum/pathology ; Progression-Free Survival ; Prospective Studies ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Tegafur/administration & dosage ; Tegafur/adverse effects ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Autorzy:: Jiang Z; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sun Y; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhang W; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Cui C; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang L; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zhou A; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Pokaż więcej
Źródło:: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2020 Jun; Vol. 16 (3), pp. 180-186. Date of Electronic Publication: 2020 Feb 20.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Capecitabine/*therapeutic use
Chemotherapy, Adjuvant/*methods
Oxaliplatin/*therapeutic use
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*surgery
Tegafur/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Capecitabine/pharmacology ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Oxaliplatin/pharmacology ; Oxonic Acid/pharmacology ; Retrospective Studies ; Stomach Neoplasms/pathology ; Survival Rate ; Tegafur/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Autorzy:: Hirahara N; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan. .
Matsubara T; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Kaji S; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Yamamoto T; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Hyakudomi R; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Takai K; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Ishitobi K; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Uchida Y; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Tajima Y; Department of Digestive and General Surgery, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Oct 01; Vol. 21 (1), pp. 1073. Date of Electronic Publication: 2021 Oct 01.
Typ publikacji:: Clinical Trial, Phase II; Journal Article
MeSH Terms:: Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Stomach Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Aged ; Anemia/chemically induced ; Anorexia/chemically induced ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant/adverse effects ; Chemotherapy, Adjuvant/methods ; Chemotherapy-Induced Febrile Neutropenia/etiology ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Docetaxel/administration & dosage ; Docetaxel/adverse effects ; Drug Administration Schedule ; Drug Combinations ; Fatigue/chemically induced ; Feasibility Studies ; Female ; Humans ; Leukopenia/chemically induced ; Male ; Middle Aged ; Neutropenia/chemically induced ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Patient Compliance ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Tegafur/administration & dosage ; Tegafur/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study.
Autorzy:: Venerito M; Otto-von-Guericke University Hospital, Department of Gastroenterology, Hepatology and Infectious Diseases, Leipziger Str. 44, 39120, Magdeburg, Germany. .; Pokaż więcej
Źródło:: Drugs in R&D [Drugs R D] 2019 Jun; Vol. 19 (2), pp. 141-148.
Typ publikacji:: Journal Article; Multicenter Study; Observational Study
MeSH Terms:: Adenocarcinoma/*drug therapy
Antimetabolites, Antineoplastic/*administration & dosage
Esophageal Neoplasms/*drug therapy
Oxonic Acid/*administration & dosage
Stomach Neoplasms/*drug therapy
Tegafur/*administration & dosage
Adenocarcinoma/pathology ; Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/adverse effects ; Dose-Response Relationship, Drug ; Drug Combinations ; Esophageal Neoplasms/pathology ; Esophagogastric Junction/pathology ; Europe ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Oxonic Acid/adverse effects ; Stomach Neoplasms/pathology ; Tegafur/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
Autorzy:: Yen HH; Department of Surgery, National Taiwan University Biomedical Park Hospital, Hsinchu County, Taiwan.; Department of Surgery, National Taiwan University Hospital, No. 7 Chung-Shan South Rd, Zhongzheng District, Taipei, 10002, Taiwan.
Chen CN; Department of Surgery, National Taiwan University Hospital, No. 7 Chung-Shan South Rd, Zhongzheng District, Taipei, 10002, Taiwan.
Yeh CC; Department of Surgery, National Taiwan University Hospital, No. 7 Chung-Shan South Rd, Zhongzheng District, Taipei, 10002, Taiwan.; Department of Medical Education, National Taiwan University Hospital, Taipei, Taiwan.
Lai IR; Department of Surgery, National Taiwan University Hospital, No. 7 Chung-Shan South Rd, Zhongzheng District, Taipei, 10002, Taiwan. .; Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan. .; Pokaż więcej
Źródło:: World journal of surgical oncology [World J Surg Oncol] 2021 Apr 17; Vol. 19 (1), pp. 124. Date of Electronic Publication: 2021 Apr 17.
Typ publikacji:: Journal Article
MeSH Terms:: Antimetabolites, Antineoplastic/*therapeutic use
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*drug therapy
Tegafur/*therapeutic use
Uracil/*therapeutic use
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant ; Cohort Studies ; Disease-Free Survival ; Drug Combinations ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Prognosis ; Stomach Neoplasms/pathology ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.
Autorzy:: Lee CK; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Jung M; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Kim HS; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Jung I; Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea.
Shin DB; Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea.
Kang SY; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
Zang DY; Division of Hemato-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea.
Kim KH; Division of HematologyOncology, Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Lee MH; Division of Hematology-Oncology, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
Kim BS; Division of HematoOncology, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Korea.
Lee KH; Division of Hematology-Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Cheong JH; Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Hyung WJ; Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Noh SH; Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Chung HC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Song-Dang Institutefor Cancer Research, Yonsei University College of Medicine, Seoul, Korea.; Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Rha SY; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Song-Dang Institutefor Cancer Research, Yonsei University College of Medicine, Seoul, Korea.; Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.; Pokaż więcej
Źródło:: Cancer research and treatment [Cancer Res Treat] 2019 Jan; Vol. 51 (1), pp. 1-11. Date of Electronic Publication: 2018 Feb 05.
Typ publikacji:: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Cisplatin/*administration & dosage
Docetaxel/*administration & dosage
Oxonic Acid/*administration & dosage
Stomach Neoplasms/*drug therapy
Tegafur/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant/adverse effects ; Cisplatin/adverse effects ; Docetaxel/adverse effects ; Docetaxel/therapeutic use ; Dose-Response Relationship, Drug ; Drug Combinations ; Female ; Gastrectomy ; Humans ; Male ; Middle Aged ; Oxonic Acid/adverse effects ; Republic of Korea ; Stomach Neoplasms/surgery ; Survival Analysis ; Tegafur/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Autorzy:: Mori M; Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan. .
Shuto K; Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.
Kosugi C; Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.
Narushima K; Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.
Hayashi H; Center for Frontier Medical Engineering, Chiba University, Chiba, Japan.
Matsubara H; Department of Frontier Surgery, Graduate School of Medical and Pharmaceutical Science, Chiba University, Chiba, Japan.
Koda K; Department of Surgery, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2018 Dec 17; Vol. 18 (1), pp. 1261. Date of Electronic Publication: 2018 Dec 17.
Typ publikacji:: Journal Article
MeSH Terms:: Antimetabolites, Antineoplastic/*administration & dosage
Neutrophils/*cytology
Oxonic Acid/*administration & dosage
Stomach Neoplasms/*blood
Stomach Neoplasms/*drug therapy
Tegafur/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/therapeutic use ; Chemotherapy, Adjuvant ; Drug Combinations ; Female ; Gastrectomy ; Humans ; Lymphocyte Count ; Male ; Middle Aged ; Neoplasm Staging ; Oxonic Acid/therapeutic use ; Prognosis ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Survival Analysis ; Tegafur/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Autorzy:: Feng Q; Department of Gastroenterology, Liaocheng People's Hospital, Liaocheng 252000, China.
Zhao JR; Department of Gastroenterology, Liaocheng People's Hospital, Liaocheng 252000, China.
Zhang AX; Department of Gastroenterology, Liaocheng People's Hospital, Liaocheng 252000, China.
Li SL; Department of Gastroenterology, Liaocheng People's Hospital, Liaocheng 252000, China.; Pokaż więcej
Źródło:: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2018 Sep 23; Vol. 40 (9), pp. 696-702.
Typ publikacji:: Journal Article
MeSH Terms:: Neoplastic Cells, Circulating*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cyclobutanes/*administration & dosage
Organoplatinum Compounds/*administration & dosage
Oxonic Acid/*administration & dosage
Stomach Neoplasms/*drug therapy
Tegafur/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cyclobutanes/adverse effects ; Disease Progression ; Disease-Free Survival ; Drug Combinations ; Humans ; Organoplatinum Compounds/adverse effects ; Oxonic Acid/adverse effects ; Prognosis ; Remission Induction ; Retrospective Studies ; Stomach Neoplasms/blood ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Tegafur/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial.
Autorzy:: Wang X; Department of General Surgery & Institute of General Surgery, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, 100853, China.
Li S; Department of General Surgery & Institute of General Surgery, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, 100853, China.
Sun Y; Department of General Surgery, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Xuhui District, Shanghai, 200032, China.
Li K; Department of Surgical Oncology, The First Hospital of China Medical University, No.155 Nanjing Street North, Heping District, Shenyang, 110001, China.
Shen X; Division of Gastrointestinal Surgery, The Second Affiliated Hospital of Wenzhou Medical University, No.109 West Xueyuan Road, Wenzhou, 325027, China.
Xue Y; Department of Gastroenterological Surgery, Harbin Medical University Cancer Hospital, No.150 Haping Road, Nangang District, Harbin, 150081, China.
Liang P; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Dalian Medical University, No.222 Zhongshan Road, Xigang District, Dalian, 116011, China.
Li G; Institute of General Surgery, General Hospital of Eastern Theater Command of Chinese PLA, No.305 East Zhongshan Road, Xuanwu District, Nanjing, 210002, China.
Chen L; Department of Gastrointestinal Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, No.420 Fuma Road, Jinan District, Fuzhou, 350014, China.
Zhao Q; Department of General Surgery, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang, 050011, China.
Li G; Department of General Surgery, Nanfang Hospital, Southern Medical University, No.1838 Guangzhoudadaobei Road, Guangzhou, 510515, China.
Fu W; Department of General Surgery, Tianjin Medical University General Hospital, No.154 Anshan Road, Heping District, Tianjin, 300052, China.
Liang H; Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital, West Huan-Hu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China.
Xin H; Department of General Surgery, Shanxi Provincial Cancer Hospital, No.3 Zhigongxincun, Xinghualing District, Taiyuan, 030013, China.
Suo J; Department of General Surgery, The First Bethune Hospital of Jilin University, No.71 Xinmindajie Street, Changchun, 130021, China.
Fang X; Department of General Surgery, China-Japan Union Hospital of Jilin University, No.126 Xi'antai Avenue, Changchun, 130033, China.
Zheng Z; Department of Gastric Surgery, Liaoning Cancer Hospital and Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang, 110042, China.
Xu Z; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Gulou District, Nanjing, 210029, China.
Chen H; Department of General Surgery, Jiangsu Cancer Hospital (Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital), No.42 Baiziting, Nanjing, 210009, China.
Zhou Y; Department of General Surgery, The Affiliated Hospital of Qingdao University, No.16 Jiangsu Road, Shinan District, Qingdao, 266003, China.
He Y; Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, No.58 Zhongshaner Road, Guangzhou, 510080, China.
Huang H; Department of Gastric Surgery, Fudan University Shanghai Cancer Center, No.270 Dongan Road, Xuhui District, Shanghai, 200032, China.
Zhu L; Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, No.3 East Qingchun Road, Jianggan District, Hangzhou, 310016, China.
Yang K; Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, No.37 Guoxue Alley, Wuhou District, Chengdu, 610041, China.
Ji J; Department of Gastrointestinal Surgery, Peking University Cancer Hospital, No.52 Fucheng Road, Haidian District, Beijing, 100142, China.
Ye Y; Department of Gastroenterological Surgery, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Zhang Z; Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, No.95 Yongan Road, Xicheng District, Beijing, 100050, China.
Li F; Department of General Surgery, Xuanwu Hospital, Capital Medical University, No.45 Changchun Street, Xicheng District, Beijing, 100053, China.
Wang X; Department of General Surgery, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Tian Y; Department of Pancreatic and Gastric Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, No.17 Panjiayuannanli, Chaoyang District, Beijing, 100021, China.
Park S; Division of Upper GI Surgery, Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, 73 Goryeodae-ro Seongbuk-gu, Seoul, 02841, South Korea.
Chen L; Department of General Surgery & Institute of General Surgery, Chinese PLA General Hospital, No.28 Fuxing Road, Haidian District, Beijing, 100853, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Jan 05; Vol. 21 (1), pp. 20. Date of Electronic Publication: 2021 Jan 05.
Typ publikacji:: Clinical Trial Protocol; Journal Article
MeSH Terms:: Neoadjuvant Therapy*
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Stomach Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Adolescent ; Adult ; Aged ; Chemotherapy, Adjuvant ; Clinical Trials, Phase III as Topic ; Drug Combinations ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multicenter Studies as Topic ; Oxaliplatin/administration & dosage ; Oxonic Acid/administration & dosage ; Prognosis ; Prospective Studies ; Randomized Controlled Trials as Topic ; Research Design ; Stomach Neoplasms/pathology ; Tegafur/administration & dosage ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
Autorzy:: Zhao Q; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Lian C; Surgical Oncology, Changzhi Medical College Affiliated Peace Hospital, Changzhi, Shanxi, China.
Huo Z; Gastrointestinal Tumor Surgery, Xingtai People's Hospital, Xingtai, China.
Li M; General Surgery, The First Hospital of Shijiazhuang, Shijiazhuang, China.
Liu Y; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Fan L; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Tan B; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhao X; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhang Z; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Wang D; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Liu Y; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Guo H; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yang P; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Tian Y; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Li Y; Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2020 Aug; Vol. 9 (16), pp. 5731-5745. Date of Electronic Publication: 2020 Jun 24.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoadjuvant Therapy/*methods
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*surgery
Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Capecitabine/administration & dosage ; Chemotherapy, Adjuvant/methods ; Confidence Intervals ; Disease-Free Survival ; Drug Combinations ; Female ; Humans ; Lymph Nodes/pathology ; Male ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Oxaliplatin/administration & dosage ; Oxaloacetates/administration & dosage ; Oxonic Acid/administration & dosage ; Prognosis ; ROC Curve ; Sample Size ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Tegafur/administration & dosage
SCR Protocol:: XELOX

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Autorzy:: Ito S; Department of Gastroenterological Surgery, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. .
Ohashi Y; Department of Integrated Science and Engineering for Sustainable Society, Chuo University, 1-13-27 Kasuga, Bunkyo-ku, Tokyo, 112-8551, Japan.
Sasako M; Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya City, Hyogo, 663-8501, Japan.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2018 Apr 20; Vol. 18 (1), pp. 449. Date of Electronic Publication: 2018 Apr 20.
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antimetabolites, Antineoplastic/*therapeutic use
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*mortality
Tegafur/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Drug Combinations ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Oxonic Acid/administration & dosage ; Oxonic Acid/adverse effects ; Retreatment ; Stomach Neoplasms/pathology ; Survival Analysis ; Tegafur/administration & dosage ; Tegafur/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Autorzy:: Kawamoto Y; Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Komatsu Y; Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan. .
Yuki S; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Sawada K; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Muranaka T; Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Harada K; Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Nakatsumi H; Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Fukushima H; Department of Gastroenterology, JCHO, Sapporo Hokushin Hospital, Sapporo, Japan.
Ishiguro A; Department of Medical Oncology, Teine Keijinkai Hospital, Sapporo, Japan.
Dazai M; Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan.
Hatanaka K; Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan.
Nakamura M; Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan.
Iwanaga I; Department of Gastroenterology, Japanese Red Cross Kitami Hospital, Kitami, Japan.
Uebayashi M; Department of Gastroenterology, Japanese Red Cross Kitami Hospital, Kitami, Japan.
Sogabe S; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Kobayashi Y; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Miyagishima T; Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan.
Ono K; Hokkaido University Hospital Clinical Research and Medical Innovation Center, Sapporo, Japan.
Sakamoto N; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Sakata Y; CEO, Misawa City Hospital, Misawa, Japan.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2017 Dec 08; Vol. 17 (1), pp. 837. Date of Electronic Publication: 2017 Dec 08.
Typ publikacji:: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
MeSH Terms:: Albumins*/administration & dosage
Albumins*/therapeutic use
Antineoplastic Combined Chemotherapy Protocols*/administration & dosage
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Organoplatinum Compounds*/administration & dosage
Organoplatinum Compounds*/therapeutic use
Oxonic Acid*/administration & dosage
Oxonic Acid*/therapeutic use
Paclitaxel*/administration & dosage
Paclitaxel*/therapeutic use
Tegafur*/administration & dosage
Tegafur*/therapeutic use
Stomach Neoplasms/*drug therapy
Adult ; Drug Combinations ; Humans ; Oxaliplatin ; Stomach Neoplasms/mortality ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
Autorzy:: Saeki H; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. .
Emi Y; Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
Oki E; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Tokunaga S; Medical Information Center, Kyushu University Hospital, Fukuoka, Japan.
Kakeji Y; Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan.
Akagi Y; Department of Surgery, Kurume University School of Medicine, Fukuoka, Japan.
Baba H; Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Baba E; Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Maehara Y; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.; Pokaż więcej
Corporate Authors:: Kyushu Study group of Clinical Cancer (KSCC)
Źródło:: BMC cancer [BMC Cancer] 2018 Jan 08; Vol. 18 (1), pp. 57. Date of Electronic Publication: 2018 Jan 08.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Organoplatinum Compounds/*administration & dosage
Oxonic Acid/*administration & dosage
Stomach Neoplasms/*drug therapy
Tegafur/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Disease-Free Survival ; Drug Combinations ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Humans ; Japan/epidemiology ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/drug therapy ; Organoplatinum Compounds/adverse effects ; Oxaliplatin ; Oxonic Acid/adverse effects ; Receptor, ErbB-2/genetics ; Stomach Neoplasms/genetics ; Stomach Neoplasms/pathology ; Tegafur/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.
Autorzy:: Nishibeppu K; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Komatsu S; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan. .
Imamura T; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Kiuchi J; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Kishimoto T; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Arita T; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Kosuga T; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Konishi H; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Kubota T; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Shiozaki A; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Fujiwara H; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Okamoto K; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Otsuji E; Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2020 Feb 21; Vol. 10 (1), pp. 3161. Date of Electronic Publication: 2020 Feb 21.
Typ publikacji:: Journal Article
MeSH Terms:: Drug Resistance, Neoplasm*
Biomarkers, Tumor/*blood
MicroRNAs/*blood
Oxonic Acid/*therapeutic use
Stomach Neoplasms/*blood
Tegafur/*therapeutic use
Animals ; Cell Line, Tumor ; Cell Movement ; Cell Survival ; Disease-Free Survival ; Drug Combinations ; Female ; Fluorouracil ; Gastrectomy ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local ; Organic Anion Transporters, Sodium-Independent/genetics ; Prognosis ; Proportional Hazards Models

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Oxonic Acid"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język